AIMS: Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. METHODS AND RESULTS: We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existing heart disease and in-hospital mortality. A total of 16 511 patients with COVID-19 were included (21.1% aged 66-75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male, and often had other comorbid conditions when compared with those without. Mortality was higher in patients with cardiac disease (29.7%; n = 1545 vs. 15.9%; n = 1797). However, following multivariable adjustment, this difference was not significant [adjusted risk ratio (aRR) 1.08, 95% confidence interval (CI) 1.02-1.15; P = 0.12 (corrected for multiple testing)]. Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure (aRR 1.19, 95% CI 1.10-1.30; P < 0.018) particularly for severe (New York Heart Association class III/IV) heart failure (aRR 1.41, 95% CI 1.20-1.64; P < 0.018). None of the other heart disease subtypes, including ischaemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients. CONCLUSION: Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare during hospitalization. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. METHODS AND RESULTS: We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existing heart disease and in-hospital mortality. A total of 16 511 patients with COVID-19 were included (21.1% aged 66-75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male, and often had other comorbid conditions when compared with those without. Mortality was higher in patients with cardiac disease (29.7%; n = 1545 vs. 15.9%; n = 1797). However, following multivariable adjustment, this difference was not significant [adjusted risk ratio (aRR) 1.08, 95% confidence interval (CI) 1.02-1.15; P = 0.12 (corrected for multiple testing)]. Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure (aRR 1.19, 95% CI 1.10-1.30; P < 0.018) particularly for severe (New York Heart Association class III/IV) heart failure (aRR 1.41, 95% CI 1.20-1.64; P < 0.018). None of the other heart disease subtypes, including ischaemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients. CONCLUSION: Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare during hospitalization. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Joseph Y Chu; Gordon W Moe; Manav V Vyas; Robert Chen; Chi-Ming Chow; Milan Gupta; Yosuf Kaliwal; Maria Koh; Dennis T Ko; Peter P Liu Journal: CJC Open Date: 2022-06-27
Authors: R R van de Leur; H Bleijendaal; K Taha; T Mast; J M I H Gho; M Linschoten; B van Rees; M T H M Henkens; S Heymans; N Sturkenboom; R A Tio; J A Offerhaus; W L Bor; M Maarse; H E Haerkens-Arends; M Z H Kolk; A C J van der Lingen; J J Selder; E E Wierda; P F M M van Bergen; M M Winter; A H Zwinderman; P A Doevendans; P van der Harst; Y M Pinto; F W Asselbergs; R van Es; F V Y Tjong Journal: Neth Heart J Date: 2022-03-17 Impact factor: 2.854
Authors: Joost A Offerhaus; Linda P T Joosten; Maarten van Smeden; Marijke Linschoten; Hidde Bleijendaal; Robert Tieleman; Arthur A M Wilde; Frans H Rutten; Geert-Jan Geersing; Carol Ann Remme Journal: Int J Cardiol Heart Vasc Date: 2022-02-04
Authors: M T H M Henkens; A G Raafs; F W Asselbergs; F J H Magdelijns; J A J Verdonschot; M Linschoten; M van Smeden; P Wang; B H M van der Hooft; R Tieleman; M L F Janssen; R M A Ter Bekke; M R Hazebroek; I C C van der Horst; S R B Heymans Journal: BMC Geriatr Date: 2022-03-05 Impact factor: 3.921
Authors: Ewan McFarlane; Marijke Linschoten; Folkert W Asselbergs; Peter S Lacy; Dawid Jedrzejewski; Bryan Williams Journal: Hypertens Res Date: 2022-03-29 Impact factor: 5.528